On this page
Gentamicin Sulfate
Overview
Active ingredients
Source: NDC Directory| Ingredient | Strength | RxCUI | Monograph |
|---|---|---|---|
| Gentamicin Sulfate | 3 mg/mL | 1870650 | View |
Forms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Aminoglycoside Antibacterial [EPC] | EPC | All 66 members |
| Aminoglycosides [CS] | CS | All 66 members |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 064048-001 | GENTAMICIN SULFATE | SOLUTION/DROPS | GENTAMICIN SULFATE | Prescription | AT |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Supplement | 14 | Manufacturing (CMC) | Approved | November 27, 2001 | — |
| Supplement | 13 | Manufacturing (CMC) | Approved | August 29, 2001 | — |
| Supplement | 12 | Manufacturing (CMC) | Approved | March 7, 2001 | — |
| Supplement | 11 | Manufacturing (CMC) | Approved | October 5, 2000 | — |
| Supplement | 10 | Manufacturing (CMC) | Approved | June 27, 2000 | — |
| Supplement | 7 | Manufacturing (CMC) | Approved | May 18, 2000 | — |
| Supplement | 9 | Manufacturing (CMC) | Approved | May 15, 2000 | — |
| Supplement | 8 | Manufacturing (CMC) | Approved | April 28, 2000 | — |
| Supplement | 6 | Manufacturing (CMC) | Approved | June 7, 1999 | — |
| Supplement | 5 | Manufacturing (CMC) | Approved | November 19, 1998 | — |
| Supplement | 4 | Manufacturing (CMC) | Approved | May 4, 1998 | — |
| Supplement | 3 | Manufacturing (CMC) | Approved | January 14, 1998 | — |
| Supplement | 2 | Manufacturing (CMC) | Approved | August 26, 1996 | — |
| Supplement | 1 | Manufacturing (CMC) | Approved | September 9, 1994 | — |
| Original application | 1 | Approved | May 11, 1994 | — |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260505). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS & USAGE SECTION Gentamicin sulfate ophthalmic solution, USP is indicated in the topical treatment of ocular bacterial infections including conjunctivitis, keratitis, keratoconjunctivitis, corneal ulcers, blepharitis, blepharoconjunctivitis, acute meibomianitis, and dacryocystitis, caused by susceptible strains of the following microorganisms: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, Enterobacter aerogenes, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Neisseria gonorrhoeae, Pseudomonas aeruginosa, and Serratia marcescens.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION Gentamicin Sulfate sterile ophthalmic solution; Instill one or two drops into the affected eye(s) every four hours. In severe infections, dosage may be increased to as much as two drops once every hour.
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS SECTION Gentamicin sulfate ophthalmic solution, USP is contraindicated in patients with known hypersensitivity to any of its components.
Warnings
openFDA Drug LabelingWARNINGS SECTION NOT FOR INJECTION INTO THE EYE. Gentamicin sulfate ophthalmic solution, USP is not for injection. It should never be injected subconjunctivally, nor should it be directly introduced into the anterior chamber of the eye.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS Bacterial and fungal corneal ulcers have developed during treatment with gentamicin ophthalmic preparations. The most frequently reported adverse reactions are ocular burning and irritation upon drug instillation, non-specific conjunctivitis, conjunctival epithelial defects and conjunctival hyperemia. Other adverse reactions which have occurred rarely are allergic reactions, thrombocytopenic purpura and hallucinations. To report SUSPECTED ADVERSE REACTIONS, contact Bausch & Lomb Incorporated at 1-800-553-5340 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Description
openFDA Drug LabelingDESCRIPTION Gentamicin sulfate ophthalmic solution, USP is a sterile, topical anti-infective agent for ophthalmic use. Gentamicin is obtained from cultures of Micromonospora purpurea . It is a mixture of the sulfate salts of gentamicin C 1 , C 2 , and C 1A . All three components appear to have similar antimicrobial activity. Gentamicin sulfate occurs as a white to buff powder and is soluble in water and insoluble in alcohol. The structural formula is as follows: Each mL contains: Active: gentamicin sulfate equivalent to 3 mg (0.3%) gentamicin base. Preservative: benzalkonium chloride. Inactives: edetate disodium; polyvinyl alcohol 1.4%; purified water; sodium chloride; sodium phosphate, dibasic; and hydrochloric acid and/or sodium hydroxide may be added to adjust pH. The solution is an aqueous, buffered solution with a shelf life pH range of 6.5 to 7.5. The structural formula for Gentamicin is obtained from cultures of Micromonospora purpurea. It is a mixture of the sulfate salts of gentamicin C1, C2, and C1A. All three components appear to have simi
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED Gentamicin sulfate ophthalmic solution USP, 0.3% is supplied sterile in a white LDPE plastic bottle, with a white LLDPE extended controlled drop tip and white polypropylene cap in the following size: NDC 68788-8592-5- 5 mL NOT FOR INJECTION INTO THE EYE FOR OPHTHALMIC USE ONLY Storage: Store between 2°C to 25°C (36°F to 77°F). Avoid exposure to excessive heat. KEEP OUT OF REACH OF CHILDREN. Distributed by: Bausch & Lomb Americas Inc. Bridgewater, NJ 08807 USA Manufactured by: Bausch & Lomb Incorporated Tampa, FL 33637 USA © 2022 Bausch & Lomb Incorporated or its affiliates Revised: September 2022 9116006 (Folded) 9116106 (Flat) Relabeled By: Preferred Pharmaceuticals Inc. donotuse
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: GENTAMICIN SULFATE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 50090-0569-0 | 50090-0569 | A-S Medication Solutions | 1 BOTTLE, DROPPER in 1 CARTON (50090-0569-0) / 5 mL in 1 BOTTLE, DROPPER | June 29, 2016 |
| 76420-254-05 | 76420-254 | Asclemed USA, Inc. | 1 BOTTLE, DROPPER in 1 CARTON (76420-254-05) / 5 mL in 1 BOTTLE, DROPPER | July 19, 2022 |
| 24208-580-60 | 24208-580 | Bausch & Lomb Incorporated | 1 BOTTLE, DROPPER in 1 CARTON (24208-580-60) / 5 mL in 1 BOTTLE, DROPPER | May 11, 1994 |
| 61919-106-05 | 61919-106 | DIRECT RX | 5 mL in 1 CARTON (61919-106-05) | May 7, 2015 |
| 66267-971-05 | 66267-971 | NuCare Pharmaceuticals, Inc. | 1 BOTTLE, DROPPER in 1 CARTON (66267-971-05) / 5 mL in 1 BOTTLE, DROPPER | March 16, 2017 |
| 68071-3554-5 | 68071-3554 | NuCare Pharmaceuticals,Inc. | 1 BOTTLE, DROPPER in 1 CARTON (68071-3554-5) / 5 mL in 1 BOTTLE, DROPPER | December 7, 2023 |
| 68071-4827-5 | 68071-4827 | NuCare Pharmaceuticals,Inc. | 5 mL in 1 BOX (68071-4827-5) | March 29, 2019 |
| 68788-8592-5 | 68788-8592 | Preferred Pharmaceuticals Inc. | 1 BOTTLE, DROPPER in 1 CARTON (68788-8592-5) / 5 mL in 1 BOTTLE, DROPPER | February 22, 2024 |
| 63187-560-05 | 63187-560 | Proficient Rx LP | 1 BOTTLE, DROPPER in 1 CARTON (63187-560-05) / 5 mL in 1 BOTTLE, DROPPER | December 1, 2018 |
| 63187-764-05 | 63187-764 | Proficient Rx LP | 1 BOTTLE, DROPPER in 1 CARTON (63187-764-05) / 5 mL in 1 BOTTLE, DROPPER | November 1, 2016 |
| 50090-0569 | 50090-0569 | A-S Medication Solutions | — | May 11, 1994 |
| 76420-254 | 76420-254 | Asclemed USA, Inc. | — | May 11, 1994 |
| 24208-580 | 24208-580 | Bausch & Lomb Incorporated | — | May 11, 1994 |
| 61919-106 | 61919-106 | DIRECT RX | — | January 1, 2014 |
| 66267-971 | 66267-971 | NuCare Pharmaceuticals, Inc. | — | December 13, 2006 |
| 68071-3554 | 68071-3554 | NuCare Pharmaceuticals,Inc. | — | May 11, 1994 |
| 68071-4827 | 68071-4827 | NuCare Pharmaceuticals,Inc. | — | January 5, 1998 |
| 68788-8592 | 68788-8592 | Preferred Pharmaceuticals Inc. | — | February 22, 2024 |
| 63187-560 | 63187-560 | Proficient Rx LP | — | May 11, 1994 |
| 63187-764 | 63187-764 | Proficient Rx LP | — | December 13, 2006 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
Generated September 25, 2026 · 12 sections on this page.